Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

499 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Psoriatic arthritis: pharmacoeconomic considerations.
Olivieri I, Mantovani LG, D'Angelo S, Padula A, de Portu S. Olivieri I, et al. Curr Rheumatol Rep. 2009 Aug;11(4):263-9. doi: 10.1007/s11926-009-0037-x. Curr Rheumatol Rep. 2009. PMID: 19691929
Pharmacoeconomic issues in psoriatic arthritis.
Olivieri I, D'Angelo S, Palazzi C, Padula A, Lubrano E, Mantovani LG. Olivieri I, et al. J Rheumatol Suppl. 2012 Jul;89:103-5. doi: 10.3899/jrheum.120258. J Rheumatol Suppl. 2012. PMID: 22751607 Review.
Long-term costs and outcomes in psoriatic arthritis patients not responding to conventional therapy treated with tumour necrosis factor inhibitors: the extension of the Psoriatic Arthritis Cost Evaluation (PACE) study.
Olivieri I, Cortesi PA, de Portu S, Salvarani C, Cauli A, Lubrano E, Spadaro A, Cantini F, Ciampichini R, Cutro MS, Mathieu A, Matucci-Cerinic M, Punzi L, Scarpa R, Mantovani LG; PACE Working Group. Olivieri I, et al. Clin Exp Rheumatol. 2016 Jan-Feb;34(1):68-75. Epub 2015 Dec 3. Clin Exp Rheumatol. 2016. PMID: 26633622 Clinical Trial.
The psoriatic arthritis cost evaluation study: a cost-of-illness study on tumour necrosis factor inhibitors in psoriatic arthritis patients with inadequate response to conventional therapy.
Olivieri I, de Portu S, Salvarani C, Cauli A, Lubrano E, Spadaro A, Cantini F, Cutro MS, Mathieu A, Matucci-Cerinic M, Pappone N, Punzi L, Scarpa R, Mantovani LG; PACE working group. Olivieri I, et al. Rheumatology (Oxford). 2008 Nov;47(11):1664-70. doi: 10.1093/rheumatology/ken320. Epub 2008 Aug 24. Rheumatology (Oxford). 2008. PMID: 18725374 Free PMC article.
Patients', physicians', nurses', and pharmacists' preferences on the characteristics of biologic agents used in the treatment of rheumatic diseases.
Scalone L, Sarzi-Puttini P, Sinigaglia L, Montecucco C, Giacomelli R, Lapadula G, Olivieri I, Giardino AM, Cortesi PA, Mantovani LG, Mecchia M. Scalone L, et al. Among authors: olivieri i. Patient Prefer Adherence. 2018 Oct 16;12:2153-2168. doi: 10.2147/PPA.S168458. eCollection 2018. Patient Prefer Adherence. 2018. PMID: 30410311 Free PMC article.
499 results